Cadila Pharma's JV on track for new vaccine's clinical test in India
"Our joint venture with Novavax Inc. is progressing well and remains on track to begin clinical testing of two new vaccines," Chairman Cadila Pharamaceutical Indravadan A Modi said, in a statement.
Indravadan Modi-led Cadila Pharmaceuticals said it has recieved regulatory approval for conducting rabies vaccine toxicology studies in India and clinical study of influenze vaccine is planned for 2012.
CPL Biologics (CPLB), its joint venture in India with US based Novavax Inc, is preparing to initiate clinical studies of vaccines to prevent influenza and rabies, in 2012 and 2013, resepectively, a statement said.
"Our joint venture with Novavax Inc. is progressing well and remains on track to begin clinical testing of two new vaccines," Chairman Cadila Pharamaceutical Indravadan A Modi said, in a statement.
CPLB completed positive preclinical immunogenecity studies of a rabies G-protein nanoparticle vaccine and recently recieved approval from the Review Committee on Genetic Manipulation(RCGM) to begin toxicology studies of its vaccine prior to initiating human clinical trials.
The CPLB facility at Dohlka taluka of Ahmedabad will be used initially to produce clinical supplies of the two vaccines and will later be used to produce commercial products as well.
Novavax, is a clinical stage biopharmaceutical company creating novel vaccines for infectious diseases using virus like particle and recombinant nanoparticle technology.
According to industry experts, rabies remains a serious public health hazard in India where 36 per cent of the world's deaths occur.
